Compare TWST & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TWST | COLL |
|---|---|---|
| Founded | 2013 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | 2018 | 2015 |
| Metric | TWST | COLL |
|---|---|---|
| Price | $40.36 | $47.21 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 6 |
| Target Price | $44.67 | ★ $51.17 |
| AVG Volume (30 Days) | ★ 1.2M | 502.7K |
| Earning Date | 02-02-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.63 |
| Revenue | $376,572,000.00 | ★ $757,067,000.00 |
| Revenue This Year | $15.19 | $26.35 |
| Revenue Next Year | $15.10 | $3.67 |
| P/E Ratio | ★ N/A | $29.62 |
| Revenue Growth | 20.32 | ★ 26.34 |
| 52 Week Low | $23.30 | $23.23 |
| 52 Week High | $55.33 | $50.79 |
| Indicator | TWST | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 71.61 | 50.34 |
| Support Level | $34.55 | $45.00 |
| Resistance Level | $37.73 | $49.17 |
| Average True Range (ATR) | 1.79 | 1.86 |
| MACD | 0.59 | -0.28 |
| Stochastic Oscillator | 93.96 | 41.90 |
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to realize opportunities ahead rapidly. Geographically, it derives a majority of its revenue from the United States.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.